Current understanding and management of CAR T cell-associated toxicities
JN Brudno, JN Kochenderfer - Nature Reviews Clinical Oncology, 2024 - nature.com
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of several
haematological malignancies and is being investigated in patients with various solid …
haematological malignancies and is being investigated in patients with various solid …
Remdesivir reduced mortality in immunocompromised patients hospitalized for COVID-19 across variant waves: findings from routine clinical practice
E Mozaffari, A Chandak, RL Gottlieb… - Clinical Infectious …, 2023 - academic.oup.com
Background Immunocompromised patients are at high risk of severe coronavirus disease
2019 (COVID-19) and death, yet treatment strategies for immunocompromised patients …
2019 (COVID-19) and death, yet treatment strategies for immunocompromised patients …
COVID‐19 in hematopoietic stem‐cell transplant recipients: A systematic review and meta‐analysis of clinical characteristics and outcomes
BA Randi, HR Higashino, VP Silva… - Reviews in Medical …, 2023 - Wiley Online Library
Patients who undergo hematopoietic stem‐cell transplantation (HSCT) are more susceptible
to developing severe forms of COVID‐19 with an increased risk of mortality. The aim of this …
to developing severe forms of COVID‐19 with an increased risk of mortality. The aim of this …
[HTML][HTML] Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
G Rossi, J Salmanton-García, C Cattaneo… - International Journal of …, 2023 - Elsevier
Objectives Elderly patients with hematologic malignancies face the highest risk of severe
COVID-19 outcomes. The infection's impact on different age groups remains unstudied in …
COVID-19 outcomes. The infection's impact on different age groups remains unstudied in …
[HTML][HTML] Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
J Salmanton-García, F Marchesi, F Farina… - …, 2024 - thelancet.com
Background The COVID-19 pandemic heightened risks for individuals with hematological
malignancies due to compromised immune systems, leading to more severe outcomes and …
malignancies due to compromised immune systems, leading to more severe outcomes and …
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
P Musto, J Salmanton‐García, N Sgherza… - Hematological …, 2024 - Wiley Online Library
Patients affected by multiple myeloma (MM) have an increased risk of severe acute
respiratory syndrome coronavirus type 2 (SARS‐CoV‐2) infection and subsequent …
respiratory syndrome coronavirus type 2 (SARS‐CoV‐2) infection and subsequent …
Change in Neurocognitive Function in Patients Who Receive CAR-T Cell Therapies: A Steep Hill to Climb
E Strongyli, P Evangelidis, I Sakellari, M Gavriilaki… - Pharmaceuticals, 2024 - mdpi.com
Immunotherapy with chimeric antigen receptor T (CAR-T) cell therapies has brought
substantial improvement in clinical outcomes in patients with relapsed/refractory B cell …
substantial improvement in clinical outcomes in patients with relapsed/refractory B cell …
Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: a single center …
E Xue, G Scorpio, A Ruggeri, D Clerici, F Farina… - Current Research in …, 2023 - Elsevier
Methods Starting in March 2022, Italian Medicines Agency granted access to tixagevimab/
cilgavimab as SARS-CoV-2 pre-exposure prophylaxis for all allogeneic HSCT recipients …
cilgavimab as SARS-CoV-2 pre-exposure prophylaxis for all allogeneic HSCT recipients …
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey
Study objectives This study aimed to achieve several key objectives related to patients with
haematological malignancies and COVID-19 who required ICU admission. Firstly, we …
haematological malignancies and COVID-19 who required ICU admission. Firstly, we …
Outcomes and risk factors of SARS‐CoV‐2 omicron variant in B‐cell lymphoma patients following CD19 targeted CAR‐T therapy
X Xiao, P Chen, Y Zhong, X Luo, Y Liu, Y Lu… - Cancer …, 2023 - Wiley Online Library
Background Little was known on infection and mortality rates, still less the risk factors of
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) omicron variant in B‐cell …
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) omicron variant in B‐cell …